Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer U.S. R&D Operations by Year
U.S. R&D Operations — Owned & leased laboratory/campus footprint (million sq. ft.) (M sq ft)
Pfizer U.S. R&D Operations: 7.0M sq ft in FY2025, down 22.2% from a year earlier.
Latest, FY2025
7.0
Period ended Dec 31, 2025
Change on a year earlier
-22.2%
9.0 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“In the U.S., our R&D facilities contain an aggregate of approximately 7 million square feet, with the majority of that area owned by Pfizer. Outside of the U.S., we lease R&D labs in the U.K., India and Belgium.”
Source: Form 10-K (pfe-20251231.htm, filed 2026-02-26) ↗
Reported in Form 10-K Item 2 Properties.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. R&D Operations — Owned & leased laboratory/campus footprint (million sq. ft.) (M sq ft) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.0 | -22.2% | Form 10-K (pfe-20251231.htm, filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 9.0 | – | Form 10-K (pfe-20241231.htm, filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer U.S. R&D Operations (M sq ft), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/ops-us-rd-sqft
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.